Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aimmune Therapeutics Inc.

www.aimmune.com

Latest From Aimmune Therapeutics Inc.

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies

Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic

With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.

 

Immune Disorders Advertising, Marketing & Sales

Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Allergen Research Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aimmune Therapeutics Inc.
  • Senior Management
  • Jayson Dallas, Pres. & CEO
    Eric Bjerkholt, CFO
    Jeffrey H Knapp, PhD, COO
    Daniel C Adelman, MD, CMO
    Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy
  • Contact Info
  • Aimmune Therapeutics Inc.
    Phone: (650) 614-5220
    8000 Marina Blvd.
    Ste. 300
    Brisbane, CA 94005
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register